New data demonstrate racial and ethnic disparities in access to prescription medications in persons with chronic liver disease in the USA. Here, we discuss potential health equity solutions that address structural and social determinants of health to mitigate liver health inequities in access to liver disease pharmacotherapies.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
World Health Organization. Health equity. WHO https://www.who.int/health-topics/health-equity (2022).
Tapper, E. B., Essien, U. R., Zhao, Z., Ufere, N. N. & Parikh, N. D. Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States. J. Hepatol. https://doi.org/10.1016/j.jhep.2022.02.010 (2022).
Essien, U. R., Dusetzina, S. B. & Gellad, W. F. A policy prescription for reducing health disparities-achieving pharmacoequity. JAMA 326, 1793–1794 (2021).
Marcus, J. L. et al. Disparities in initiation of direct-acting antiviral agents for hepatitis C virus infection in an insured population. Public Health Rep. 133, 452–460 (2018).
Wang, T. et al. Healthcare disparities identified between Hmong and other Asian origin groups living with chronic hepatitis B infection in Sacramento County 2014–2017. J. Community Health 45, 412–418 (2020).
Gordon, S. C. et al. Ursodeoxycholic acid treatment preferentially improves overall survival among African Americans with primary biliary cholangitis. Am. J. Gastroenterol. 115, 262–270 (2020).
Ahn, J. C. et al. Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. Hepatology https://doi.org/10.1002/hep.32527 (2022).
Jacobs, D. B. & Sommers, B. D. Using drugs to discriminate — adverse selection in the insurance marketplace. N. Engl. J. Med. 372, 399–402 (2015).
Ahn, S. & Corlette, S. State Efforts to Lower Consumer Cost-Sharing for High-Cost Prescription Drugs: Stakeholder Perspectives (Urban Institute, 2017).
Guadamuz, J. S. et al. Fewer pharmacies in Black and Hispanic/Latino neighborhoods compared with white or diverse neighborhoods, 2007-15. Health Aff. 40, 802–811 (2021).
The authors declare no competing interests.
About this article
Cite this article
Kardashian, A., Nephew, L.D. Achieving health equity in liver disease pharmacotherapy. Nat Rev Gastroenterol Hepatol 19, 489–490 (2022). https://doi.org/10.1038/s41575-022-00632-8